TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06592104: APOLLO-EPP: Phase 3 Trial of Bitopertin Oral GlyT1 Inhibitor in Erythropoietic Protoporphyria

Sponsor: Disc Medicine, Inc. · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 145 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT06592104 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06592104 Rescue Dossier →